Monatsschrift Kinderheilkunde

, Volume 160, Issue 3, pp 224–230

Therapie der juvenilen idiopathischen Arthritis (JIA)

Neue Therapiekonzepte: Biologicals
Leitthema

Zusammenfassung

Die Einführung der Biologicals in die Therapie der JIA (juvenile idiopathische Arthritis) hatte eine wesentliche Verbesserung des klinischen Outcomes der Patienten zur Folge. Das Erreichen einer dauerhaften Remission wurde zu einem realistischen Ziel. Neben den seit einiger Zeit zugelassenen TNF-α-Inhibitoren (TNF: Tumornekrosefaktor), die derzeit die größte Rolle in der Therapie der JIA spielen, ist ein CTLA-4-Ig-Fusionsmolekül (CTLA: „cytotoxic T-lymphocyte antigen“, Ig: Immunglobulin) zur Blockade der T-Zell-Stimulation in der Therapie der juvenilen Polyarthritis sowie seit kurzem auch ein Antikörper gegen den IL-6-Rezeptor (IL: Interleukin) in der Behandlung der systemischen Form der JIA (SOJIA) zugelassen. Im vorliegenden Beitrag werden die Wirkweisen, Indikationen und Nebenwirkungen von zugelassenen und nicht zugelassenen Biologicals für die Therapie der JIA beschrieben.

Schlüsselwörter

Biologicals Juvenile idiopathische Arthritis Tumornekrosefaktor α Interleukin 6 Interleukin 1β 

Therapy of juvenile idiopathic arthritis (JIA)

New therapy concepts: biologicals

Abstract

The introduction of biologicals into the therapy of juvenile idiopathic arthritis (JIA) has resulted in a substantial improvement in patient outcome. Permanent remission has become a realistic treatment goal. Apart from tumor necrosis factor (TNFα: inhibitors which play the most important role in the therapy of JIA, a cytotoxic T-lymphocyte antigen (CTLA-4) immunoglobulin fusion molecule which blocks T cell stimulation in polyarticular arthritis as well as an antibody against IL-6 receptor for systemic onset juvenile idiopathic arthritis (SOJIA) have been approved. This review describes biological principles, indications and side effects of approved and non-approved biologicals for JIA.

Keywords

Biologicals Juvenile idiopathic arthritis Tumor necrosis factor-alpha Interleukin-6 Interleukin-1 beta 

Literatur

  1. 1.
    Alexeeva EI, Valieva SI, Bzarova TM et al (2011) Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol 30:1163–1172CrossRefPubMedGoogle Scholar
  2. 2.
    Burmester GR, Mease P, Dijkmans BA et al (2009) Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 68:1863–1869CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Clifford DB, Ances B, Costello C et al (2011) Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 68:1156–1164CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Dueckers G, Guellac N, Arbogast M et al (2011) Evidence and consensus based treatment guidelines 2010 for juvenile idiopathic arthritis by the German society of paediatric rheumatology. Klin Padiatr 223: 386–394CrossRefPubMedGoogle Scholar
  5. 5.
    Giannini EH, Ilowite NT, Lovell DJ et al (2009) Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 60: 2794–2804CrossRefPubMedGoogle Scholar
  6. 6.
    Goldbach-Mansky R, Shroff SD, Wilson M et al (2008) A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 58:2432–2442CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Heiligenhaus A, Miserocchi E, Heinz C et al (2011) Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford) 50:1390–1394CrossRefGoogle Scholar
  8. 8.
    Horneff G, Schmeling H, Biedermann T et al (2004) The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 63:1638–1644CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Horneff G, De BF, Foeldvari I et al (2009) Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 68:519–525CrossRefPubMedGoogle Scholar
  10. 10.
    Horneff G, Ebert A, Fitter S et al (2009) Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis. Rheumatology (Oxford) 48:916–919CrossRefGoogle Scholar
  11. 11.
    Horneff G, Foeldvari I, Minden K et al (2011) Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatology (Oxford) 50:230–236CrossRefGoogle Scholar
  12. 12.
    Hyams J, Crandall W, Kugathasan S et al (2007) Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology 132: 863–873CrossRefPubMedGoogle Scholar
  13. 13.
    Imagawa T, Yokota S, Mori M et al (2011) Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol Jun 12. [Epub ahead of print]Google Scholar
  14. 14.
    Kotaniemi K, Saila H, Kautiainen H (2011) Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol 5:1425–1429CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Lovell DJ, Giannini EH, Reiff A et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342:763–769CrossRefPubMedGoogle Scholar
  16. 16.
    Lovell DJ, Reiff A, Ilowite NT et al (2008) Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 58:1496–1504CrossRefPubMedGoogle Scholar
  17. 17.
    Lovell DJ, Ruperto N, Goodman S, et al (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359:810–820CrossRefPubMedGoogle Scholar
  18. 18.
    Navarra SV, Guzman RM, Gallacher AE et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377:721–731CrossRefPubMedGoogle Scholar
  19. 19.
    Nigrovic PA, Mannion M, Prince FH et al (2011) Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 63:545–555CrossRefPubMedGoogle Scholar
  20. 20.
    Prakken B, Albani S, Martini A (2011) Juvenile idiopathic arthritis. Lancet 377:2138–2149CrossRefPubMedGoogle Scholar
  21. 21.
    Quartier P, Allantaz F, Cimaz R et al (2011) A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 70:747–754CrossRefPubMedGoogle Scholar
  22. 22.
    Ruperto N, Lovell DJ, Cuttica R et al (2007) A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 56:3096–3106CrossRefPubMedGoogle Scholar
  23. 23.
    Ruperto N, Lovell DJ, Quartier P et al (2008) Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372:383–391CrossRefPubMedGoogle Scholar
  24. 24.
    Ruperto N, Lovell DJ, Cuttica R et al (2010) Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 69:718–722CrossRefPubMedGoogle Scholar
  25. 25.
    Ruperto N, Lovell DJ, Quartier P et al (2010) Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 62:1792–1802CrossRefPubMedGoogle Scholar
  26. 26.
    Ruperto N, Quartier P, Wulffraat N et al (2011) A phase II study to evaluate dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum Sep 27. [Epub ahead of print]Google Scholar
  27. 27.
    Simard JF, Neovius M, Hagelberg S et al (2010) Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum 62:3776–3782CrossRefPubMedGoogle Scholar
  28. 28.
    Tynjala P, Lindahl P, Honkanen V et al (2007) Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 66: 548–550CrossRefPubMedGoogle Scholar
  29. 29.
    Dijken TD van, Vastert SJ, Gerloni VM et al (2011) Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol 38:1441–1446CrossRefPubMedGoogle Scholar
  30. 30.
    Yokota S, Imagawa T, Mori M et al (2008) Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371:998–1006CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  1. 1.Abteilung für Pädiatrische Rheumatologie, Klinik für Kinder und JugendmedizinKlinikum, RWTH AachenAachenDeutschland

Personalised recommendations